Latest News for: cll

Edit

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy ...

Cadillac News 09 Dec 2025
COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 8, 2025-- ... .
Edit

Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL

Citizen Tribune 09 Dec 2025
LBA-3. Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL. First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ....
Edit

Genmab Announces New Data from Phase 1b/2 EPCORE� CLL-1 Highlighting Potential of Epcoritamab as Monotherapy ...

Business Wire 09 Dec 2025
GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE� CLL-1 ...
Edit

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Pharmiweb 09 Dec 2025
EPCORE® CLL-1, Arm 2A (Epcoritamab Monotherapy) ... EPCORE® CLL-1, Arm 2B (Epcoritamab Lenalidomide Combination) ... EPCORE® CLL-1, Arm 2C (Epcoritamab R-CHOP Combination) ... About the EPCORE® CLL-1 Trial.
Edit

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

PR Newswire 09 Dec 2025
Lilly has begun submitting results from BRUIN CLL-313 and BRUIN CLL-314 studies to regulatory authorities with the goal of further expanding Jaypirca's label into earlier lines of therapy.
Edit

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) (Genmab A/S)

Public Technologies 08 Dec 2025
2025-12-08 22.30.00 CET Genmab A/S - Investor News Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT).
Edit

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

PR Newswire 03 Dec 2025
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor ... Lilly is studying Jaypirca in CLL/SLL in multiple Phase 3 studies.
  • 1

Article Search

tools
×
×
×
×